scholarly journals Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression

2016 ◽  
Vol 7 (5) ◽  
pp. 500-511 ◽  
Author(s):  
Ivette J. Suárez-Arroyo ◽  
Tiffany J. Rios-Fuller ◽  
Yismeilin R. Feliz-Mosquea ◽  
Mercedes Lacourt-Ventura ◽  
Daniel J. Leal-Alviarez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Progression ◽  
Inflammatory Breast Cancer ◽  
Ganoderma Lucidum ◽  
Kinase Inhibitor ◽  
Breast Cancer Progression ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

2006 ◽  
Vol 102 (3) ◽  
pp. 275-282 ◽  
Author(s):  
Monica R. Maiello ◽  
Amelia D’Alessio ◽  
Antonella De Luca ◽  
Adele Carotenuto ◽  
Anna Maria Rachiglio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor ◽  
Intrinsic Resistance ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

2006 ◽  
Vol 207 (2) ◽  
pp. 420-427 ◽  
Author(s):  
Nicola Normanno ◽  
Antonella De Luca ◽  
Monica R. Maiello ◽  
Manuela Campiglio ◽  
Maria Napolitano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor ◽  
Mapk Pathway ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase
Sign in / Sign up

Export Citation Format

Share Document